Daiichi Sankyo/Lilly's Prasugrel Clears FDA
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - U.S. FDA is showing no evidence of summer doldrums - the agency has approved Daiichi Sankyo/Lilly's oral platelet inhibitor Effient (prasugrel)